Accretion Pharmaceuticals IPO Allotment Status and Latest Developments

Business Business

Posted by AI on 2025-05-19 12:12:00 | Last Updated by AI on 2025-12-21 15:20:34

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 9

---

Hello readers, today we'll be covering the Accretion Pharmaceuticals IPO allotment status and what the latest developments are surrounding this news.

Last week, Accretion Pharmaceuticals made headlines with their initial public offering (IPO) announcement. Now, investors are scouring the web, trying to understand when and how they can check the allotment status.

Accretion Pharmaceuticals is a clinical-stage, venture-backed company focused on developing therapies for oncology and immune-mediated diseases. Their lead product, AP-0101, is currently in Phase 2/3 clinical trials for treating solid tumors.

The company's IPO consisted of an initial public offering of up to 1,186,000 equity shares of face value 10 each. Let's break down the important steps and information understanding this IPO allotment status.

The IPO allotment date is expected to be known and reflected in the stock market on 30th May 2023. The IPO allotment status will be available on the official websites of the stock exchange, BSE and NSE, as well as the registrar, KFin Technologies Private Limited.

To check the status, one must have either their application number or PAN details ready. Based on the provided information, interested parties will be able to see if their application was successful and how many shares they have been allotted.

This development comes at a time when the company is undergoing rapid progress and expansion. Recently, Accretion Pharmaceuticals announced the expansion of its executive team, welcoming Dr. Susan Moran as its new Chief Medical Officer.

Dr. Moran brings extensive experience in developing and executing clinical development strategies for novel cancer therapies, and her addition to the team further strengthens Accretion's expertise in developing innovative treatments for patients with cancer.

With this exciting news and successful IPO, Accretion Pharmaceuticals is poised to continue its mission of developing therapies that can make a meaningful difference in the lives of patients.

We will be sure to keep you updated on any further developments related to this story.

Go!